Rhenman & Partners Asset Management AB decreased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 66.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,000 shares of the biopharmaceutical company's stock after selling 33,350 shares during the period. Rhenman & Partners Asset Management AB's holdings in Alnylam Pharmaceuticals were worth $4,000,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in the business. Regeneron Pharmaceuticals Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth $1,045,822,000. Norges Bank acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $577,941,000. Raymond James Financial Inc. purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth about $65,295,000. Jennison Associates LLC acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter worth about $61,160,000. Finally, Proficio Capital Partners LLC lifted its stake in Alnylam Pharmaceuticals by 25,929.6% during the fourth quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company's stock valued at $45,570,000 after buying an additional 192,916 shares in the last quarter. Institutional investors own 92.97% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms have recently issued reports on ALNY. William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Citigroup increased their target price on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a report on Friday, March 21st. Needham & Company LLC reiterated a "buy" rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday. Stifel Nicolaus increased their price objective on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a research note on Monday, March 31st. Finally, StockNews.com downgraded Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $316.25.
View Our Latest Stock Report on Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Stock Performance
ALNY traded down $20.10 during trading on Thursday, reaching $223.17. 728,270 shares of the company's stock were exchanged, compared to its average volume of 854,296. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a market capitalization of $29.03 billion, a P/E ratio of -102.93 and a beta of 0.30. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The business has a 50 day moving average price of $254.83 and a 200 day moving average price of $258.93.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, EVP Kevin Joseph Fitzgerald sold 663 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the sale, the executive vice president now owns 14,321 shares of the company's stock, valued at approximately $3,654,862.41. This trade represents a 4.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Phillip A. Sharp sold 11,250 shares of the business's stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. Insiders sold 71,234 shares of company stock worth $19,958,097 over the last three months. 1.50% of the stock is currently owned by corporate insiders.
About Alnylam Pharmaceuticals
(
Free Report)
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Further Reading
Before you consider Alnylam Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.
While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
